prolymphocytic leukemia

Summary

Summary: A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.

Top Publications

  1. Lee S, Robinson M, Morris J, Mirtsching B, Shen D, Chan C. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature. Surv Ophthalmol. 2004;49:525-36 pubmed
    T-cell prolymphocytic leukemia is a rare and highly aggressive hematological neoplasm. A patient with T-cell prolymphocytic leukemia presented with bilateral perilimbal conjunctival infiltrates...
  2. Dearden C. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm. 2004;19:391-8 pubmed
    ..trials have demonstrated that alemtuzumab has clinical activity in mature T-cell diseases such as T-cell prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma (CTCL)...
  3. Durig J, Bug S, Klein Hitpass L, Boes T, Jöns T, Martin Subero J, et al. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q1. Leukemia. 2007;21:2153-63 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive lymphoma derived from mature T cells, which is, in most cases, characterized by the presence of an inv(14)(q11q32)/t(14;14)(q11;q32) and a characteristic pattern of secondary ..
  4. Foucar K. Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome. Am J Clin Pathol. 2007;127:496-510 pubmed
    ..1 was devoted to case presentations with discussions of 3 types of mature T-cell leukemias--T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome...
  5. Thorat K, Gujral S, Kumar A, Nair C. Small cell variant of T-cell prolymphocytic leukemia exhibiting suppressor phenotype. Leuk Lymphoma. 2006;47:1711-3 pubmed
  6. Costa D, Queralt R, Aymerich M, Carrió A, Rozman M, Vallespi T, et al. High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. Cancer Genet Cytogenet. 2003;147:36-43 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare postthymic T-cell disorder that may show different morphologic variants and a very aggressive clinical behavior...
  7. Soulier J, Pierron G, Vecchione D, Garand R, Brizard F, Sigaux F, et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001;31:248-54 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare malignant proliferation of lymphoid cells with a postthymic phenotype...
  8. Perz J, Topaly J, Fruehauf S, Hensel M, Ho A. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43:149-51 pubmed
    ..of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment...
  9. Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar Shira A, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 1997;3:1155-9 pubmed
    ..of AT patients to develop neoplasms of the T-cell lineage, we analyzed a series of T-cell leukemias (T-prolymphocytic leukemia, or T-PLL) in non-AT patients in search of genomic changes associated with the development of this ..

More Information

Publications94

  1. Hoh F, Yang Y, Guignard L, Padilla A, Stern M, Lhoste J, et al. Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. Structure. 1998;6:147-55 pubmed
    ..One type of T-cell leukemia, T-cell prolymphocytic leukemia, is consistently associated with chromosome rearrangements characterized by the juxtaposition of the TCRA ..
  2. Toyota S, Nakamura N, Dan K. T-cell prolymphocytic leukemia with hemorrhagic gastrointestinal involvement and a new chromosomal abnormality. Int J Hematol. 2002;75:314-7 pubmed
    We report a case of T-cell prolymphocytic leukemia in a 56-year-old woman who exhibited hemorrhaging with gastric involvement as the first manifestation...
  3. Dhar Munshi S, Alton P, Ayliffe W. Masquerade syndrome: T-cell prolymphocytic leukemia presenting as panuveitis. Am J Ophthalmol. 2001;132:275-7 pubmed
    To report a case of T-cell prolymphocytic leukemia with panuveitis as the primary presenting feature.
  4. Montillo M, Tedeschi A, O Brien S, Di Raimondo F, Lerner S, Ferrajoli A, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer. 2003;97:114-20 pubmed
    ..To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL).
  5. Yamaguchi M, Yamamoto K, Miki T, Mizutani S, Miura O. T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency. Cancer Genet Cytogenet. 2003;146:22-6 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell malignancy and is similar to a mature T-cell leukemia seen in some patients with ataxia telangiectasia, which is a recessive hereditary chromosomal instability syndrome ..
  6. Michallet A, Lesca G, Radford Weiss I, Delarue R, Varet B, Buzyn A. T-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome. Ann Hematol. 2003;82:515-517 pubmed publisher
    ..The diagnosis of T-cell prolymphocytic leukemia (T-PLL) was confirmed by cytological and immunological assays (TdT(-), CD2(+), CD5(+), CD3m, and CD7(+))...
  7. Dearden C. T-cell prolymphocytic leukemia. Med Oncol. 2006;23:17-22 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive post-thymic malignancy with poor response to conventional treatment and short survival...
  8. Dearden C, Matutes E, Cazin B, Tjønnfjord G, Parreira A, Nomdedeu B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721-6 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high remission induction rate with the human CD52 antibody, CAMPATH-1H...
  9. McCune S, Gockerman J, Moore J, DeCastro C, Bass A, Chao N, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma. 2002;43:1007-11 pubmed
    Twenty-three adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) were treated for up to 12 weeks with the anti-CD52 monoclonal antibody alemtuzumab...
  10. Tamayose K, Sato N, Ando J, Sugimoto K, Oshimi K. CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature. Am J Hematol. 2002;71:331-5 pubmed
    We report a case of CD3-negative, CD20-positive T-cell prolymphocytic leukemia (T-PLL). The leukemic cells were of medium-to-large size, mature-looking, and did not have cytoplasmic granules...
  11. Herling M, Patel K, Teitell M, Konopleva M, Ravandi F, Kobayashi R, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111:328-37 pubmed
    ..1 (TCL1) oncoprotein is overexpressed by chromosomal rearrangement in the majority of cases of T-cell prolymphocytic leukemia (T-PLL)...
  12. Nguyen D, Cao T, Dugan K, Starcher S, Fechter R, Coutre S. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma. 2002;3:105-10 pubmed
    ..is effective therapy for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL), but it is associated with profound lymphopenia and deficiencies in cell-mediated immunity...
  13. Crisostomo R, Fernandez J, Caceres W. Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia. Leuk Res. 2007;31:699-701 pubmed
    ..The patient was treated with six cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Complete remission was achieved according to the criteria defined by National Cancer Institute Working Group for CLL. ..
  14. Gritti C, Choukroun V, Soulier J, Madani A, Dastot H, Leblond V, et al. Alternative origin of p13MTCP1-encoding transcripts in mature T-cell proliferations with t(X;14) translocations. Oncogene. 1997;15:1329-35 pubmed
    The MTCP1 gene is involved in the t(X;14)(q28;q11) translocation associated with T-cell prolymphocytic leukemia and related conditions...
  15. McElreath D, Angtuaco T, Staggs B, Malik A. T cell prolymphocytic leukemia: a rare cause of acute liver failure. Dig Dis Sci. 2006;51:819-21 pubmed
  16. Reindl L, Bacher U, Dicker F, Alpermann T, Kern W, Schnittger S, et al. Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms. Br J Haematol. 2010;151:25-36 pubmed publisher
    ..80·1 months, P = 0·015). In conclusion, the del(14q) is a rare recurrent alteration in diverse mature B-cell neoplasms, shows variable size but distinct clustering of breakpoints, and is associated with short time to treatment. ..
  17. Chaar B, Petruska P. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol. 2007;82:417 pubmed
  18. Cuneo A, Bigoni R, Rigolin G, Roberti M, Bardi A, Cavazzini F, et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. Haematologica. 2002;87:44-51 pubmed
    ..Eighty-two patients with CLL and related disorders, i.e. CLL/PL and prolymphocytic leukemia (PLL), without 11q- at diagnosis were sequentially ascertained at 1-2 year intervals by conventional ..
  19. Soma L, Cornfield D, Prager D, Nowell P, Bagg A. Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia?. Am J Hematol. 2002;71:224-6 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is typically associated with an aggressive clinical course, with a median survival of less than 1 year...
  20. Brito Babapulle V, Baou M, Matutes E, Morilla R, Atkinson S, Catovsky D. Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemia. Br J Haematol. 2001;114:327-32 pubmed
    ..Thus, 13q14.3 deletions could contribute to the development of overt leukaemia in T-PLL, but the involvement of more than one gene in the region cannot be excluded. ..
  21. Kojima K, Yasukawa M, Miyakuni T, Harashima A, Matsuo Y, Yano T, et al. Serum levels of parathyroid hormone-related protein are not elevated in patients with T-cell prolymphocytic leukemia. Ann Hematol. 1999;78:415-7 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare post-thymic T-cell neoplasm which shares most clinical features with adult T-cell leukemia (ATL)...
  22. Toyota S, Nakamura N, Dan K. Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype. Int J Hematol. 2005;81:66-8 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare postthymic T-cell disorder. The disease is characterized by lymphadenopathy, splenomegaly, skin lesions, a high white blood cell count, and an aggressive clinical course...
  23. Herling M, Valbuena J, Jones D, Medeiros L. Skin involvement in T-cell prolymphocytic leukemia. J Am Acad Dermatol. 2007;57:533-4 pubmed
  24. Cao T, Coutre S. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H). Hematology. 2003;8:1-6 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell lymphoproliferative disorder...
  25. Magro C, Morrison C, Heerema N, Porcu P, Sroa N, Deng A. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol. 2006;55:467-77 pubmed
    T-cell prolymphocytic leukemia (T-PLL), formerly categorized as T-cell chronic lymphocytic leukemia, is a rare and aggressive hematologic malignancy...
  26. Onciu M, Schlette E, Bueso Ramos C, Medeiros L. Leukemic mantle cell lymphoma with cells resembling prolymphocytes. Am J Clin Pathol. 2002;118:305-6; author reply 306 pubmed
  27. Hu Z, Li S, Medeiros L, Sun T. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. Hum Pathol. 2017;65:175-179 pubmed publisher
    T-prolymphocytic leukemia (T-PLL) is a rare mature T-cell neoplasm characterized by proliferation of prolymphocytes. Most cases involve the T-cell leukemia-1 (TCL1) gene at 14q11...
  28. He L, Tang J, Andersson E, Timonen S, Koschmieder S, Wennerberg K, et al. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. Cancer Res. 2018;78:2407-2418 pubmed publisher
    ..Using T-cell prolymphocytic leukemia (T-PLL) as a first case study, we show how the DCPT platform successfully predicted distinct synergistic ..
  29. Thick J, Mak Y, Metcalfe J, Beatty D, Taylor A. A gene on chromosome Xq28 associated with T-cell prolymphocytic leukemia in two patients with ataxia telangiectasia. Leukemia. 1994;8:564-73 pubmed
    ..for many years in T cells in two patients with ataxia telangiectasia (A-T), who subsequently developed T-prolymphocytic leukemia. We describe here the relationship between the translocation breakpoints in these patients with respect ..
  30. Nagai T, Izumi T, Noborio K, Takatoku M, Ohtsuki T, Machii T, et al. [Successful treatment of hairy cell leukemia prolymphocytic variant with 2'-deoxycoformycin]. Rinsho Ketsueki. 2002;43:583-5 pubmed
    ..This effect of DCF has so far been long term. More clinical studies are needed to confirm the therapeutic value of DCF. ..
  31. Ichikawa K, Noguchi M, Imai H, Sekiguchi Y, Wakabayashi M, Sawada T, et al. A case of T cell prolymphocytic leukemia involving blast transformation. Int J Hematol. 2011;93:667-672 pubmed publisher
    We report a case of T cell prolymphocytic leukemia (T-PLL) involving blast transformation. At the initial diagnosis, most peripheral blood cells demonstrated proliferation of indolent T cell small cell variants, i.e...
  32. Ferrajoli A, O Brien S, Cortes J, Giles F, Thomas D, Faderl S, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98:773-8 pubmed
    ..The most common diagnoses were chronic lymphocytic leukemia (n = 42 patients) and T-cell prolymphocytic leukemia (n = 18 patients)...
  33. Sandberg Y, Wu K, Heule F, van den Bos R, Lam K, Langerak A, et al. Clinically and genetically atypical T-cell prolymphocytic leukemia underlines the relevance of a multidisciplinary diagnostic approach. Haematologica. 2007;92:e34-6 pubmed
  34. Weston K, Mulligan S, Raison R. In vivo binding of mouse IgG via polyreactive surface IgM abrogates progressive lymphocytosis in prolymphocytic leukemia. Leuk Lymphoma. 1998;29:361-73 pubmed
    ..in vitro and in vivo binding of mouse Ig to the surface of malignant B-cells from a patient with B-cell prolymphocytic leukemia (B-PLL)...
  35. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383-9 pubmed
    ..cells obtained from 33 patients with B-cell chronic lymphocytic leukemia (B-CLL), 5 patients with prolymphocytic leukemia (PLL), and 6 patients with mantle cell lymphoma (MCL) to be lysed by rituximab and complement in vitro...
  36. Chun H, Castellvi Bel S, Wang Z, Nagourney R, Plaeger S, Becker Catania S, et al. TCL-1, MTCP-1 and TML-1 gene expression profile in non-leukemic clonal proliferations associated with ataxia-telangiectasia. Int J Cancer. 2002;97:726-31 pubmed
    ..Additional genetic alterations must occur to initiate tumorigenesis. ..
  37. Epner E, Saroya B, Hasanali Z, Loughran T. Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach. Exp Hematol. 2016;44:157-60 pubmed publisher
    ..could overcome resistance of leukemic cells to monoclonal antibody-mediated anti-tumor effects in T-cell prolymphocytic leukemia. We also reported that epigenetic agents could induce expression of the CD30 gene, thus providing a ..
  38. Noguchi M, Ropars V, Roumestand C, Suizu F. Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J. 2007;21:2273-84 pubmed
  39. Stengel A, Kern W, Zenger M, Perglerová K, Schnittger S, Haferlach T, et al. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker. Genes Chromosomes Cancer. 2016;55:82-94 pubmed publisher
    T-cell prolymphocytic leukemia (T-PLL) is a rare post-thymic T-cell neoplasm with aggressive clinical course and short overall survival...
  40. Sellner L, Bruggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, et al. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. Bone Marrow Transplant. 2017;52:544-551 pubmed publisher
    Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking...
  41. Sud A, Dearden C. T-cell Prolymphocytic Leukemia. Hematol Oncol Clin North Am. 2017;31:273-283 pubmed publisher
    T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy...
  42. Stankovic T, Stewart G, Byrd P, Fegan C, Moss P, Taylor A. ATM mutations in sporadic lymphoid tumours. Leuk Lymphoma. 2002;43:1563-71 pubmed
    ..Therefore, one of the future challenges will be to devise strategies to bypass the existing defect in response to DNA damage and activate apoptosis in ATM mutant sporadic lymphoid tumours. ..
  43. Curtin N, Schwarer A. Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility. Clin Lab Haematol. 2005;27:206-8 pubmed
    ..This case highlights the curative potential of nonmyeloablative transplantation for T-PLL as well as the potential severity of immune haemolysis secondary to minor ABO incompatibility. ..
  44. Nakajima H, Oki M, Ando K. Unusual lymphoma manifestations: case 3. CD8+ T-cell prolymphocytic leukemia. J Clin Oncol. 2004;22:560-2 pubmed
  45. Proto Siqueira R, Falcao R, de Souza C, Ismael S, Zago M. The expression of PRAME in chronic lymphoproliferative disorders. Leuk Res. 2003;27:393-6 pubmed
    ..The stronger and more frequent expression of PRAME in MCL is apparently an additional distinguishing feature on this group of lymphoproliferative disorders...
  46. Ingram P, Howman R, Leahy M, Dyer J. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis. 2007;44:e115-7 pubmed
    ..We present the first reported case of immune reconstitution syndrome associated with T lymphocyte recovery after alemtuzumab therapy...
  47. Crowley B, Woodcock B. Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab. Br J Haematol. 2002;119:279-80 pubmed
  48. Nguyen Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff Tavernier M, et al. Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genet Cytogenet. 2005;159:74-8 pubmed
    Burkitt-type acute leukemia cells were present in the bone marrow of a patient with B-prolymphocytic leukemia diagnosed from peripheral blood cell morphology. Immunophenotype analysis confirmed morphological patterns...
  49. Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K, et al. [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia]. Rinsho Ketsueki. 2005;46:527-31 pubmed
    ..After the occurrence of mild acute GVHD, the residual T-cell number decreased. The patient is still in complete remission for up to 22 months after BMT. We conclude that allogeneic SCT is effective for the treatment of T-PLL...
  50. Dearden C, Matutes E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer. 1991;64:903-6 pubmed
    ..We conclude that DCF is a useful therapy for the treatment of T-cell leukaemias, in particular Sezary syndrome and T-PLL, and should play a part in strategies to improve the natural history of this group of lymphoid malignancies...
  51. Abraham S, Braun R, Matthes T, Saurat J. A follow-up: previously reported apparent lymphomatoid contact dermatitis, now followed by T-cell prolymphocytic leukaemia. Br J Dermatol. 2006;155:633-4 pubmed
  52. Brito Babapulle V, Hamoudi R, Matutes E, Watson S, Kaczmarek P, Maljaie H, et al. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome. Br J Haematol. 2000;110:180-7 pubmed
    ..Alternatively, the frequent loss of the p53 gene could be associated with the deletion of an adjacent gene, which could be involved in the pathogenesis of these diseases...
  53. Andersen M, Christiansen D, Jensen B, Ernst P, Hauge G, Pedersen Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol. 2001;114:539-43 pubmed
  54. Wiegant J, van Gijlswijk R, Heetebrij R, Bezrookove V, Raap A, Tanke H. ULS: a versatile method of labeling nucleic acids for FISH based on a monofunctional reaction of cisplatin derivatives with guanine moieties. Cytogenet Cell Genet. 1999;87:47-52 pubmed
    ..In addition, with ULS labeling it is possible to label degraded DNA, a situation in which enzymatic labeling is known to perform unsatisfactorily...
  55. Robak T, Robak P. Current treatment options in prolymphocytic leukemia. Med Sci Monit. 2007;13:RA69-80 pubmed
    b>Prolymphocytic leukemia (PLL) is a rare lymphoproliferative disorder characterized by marked leukocytosis and splenomegaly. PLL accounts for approximately 2% of chronic lymphoid leukemias...
  56. Krejci M, Adam Z, Pour L, Brychtova Y, Mayer J, Vorlicek J. [B-cell chronic lymphocytic leukaemia and the similar states]. Vnitr Lek. 2009;55:746-65 pubmed
    ..Since monoclonal immunoglobulin is sometimes identified in patients with these diseases, it is important to consider these conditions in the differential diagnosis of the states with the presence of monoclonal immunoglobulin...
  57. Ho A, Ganeshaguru K, Knauf W, Dietz G, Trede I, Hoffbrand A, et al. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response. Leuk Res. 1989;13:269-78 pubmed
    ..Our results show that neither measurement of these enzymes nor studies of these biochemical sequelae of ADA inhibition in vitro predicts clinical responsiveness to DCF therapy...
  58. Kuriakose P, Perveen N, Maeda K, Wiktor A, Van Dyke D. Translocation (8;14)(q24;q32) as the sole cytogenetic abnormality in B-cell prolymphocytic leukemia. Cancer Genet Cytogenet. 2004;150:156-8 pubmed
    B-cell prolymphocytic leukemia is a relatively rare lymphoproliferative disorder. No specific cytogenetic abnormality has yet been associated with it...
  59. Nayak K, Shankarnarayanan -, Naik R, Khadilkar U. Prolymphocytic leukaemia--report of three cases. J Indian Med Assoc. 2004;102:379-80 pubmed
    ..Bone marrow aspiration showed diffuse involvement; and in one with minimal lymphadenopathy, lymph node aspiration showed prolymphocytes. All the three patients died within a year after diagnosis...
  60. Delgado J, Bustos J, Jimenez M, Quevedo E, Hernandez Navarro F. Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?. Leuk Lymphoma. 2002;43:2331-4 pubmed
    T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoproliferative disorder with distinctive clinical and laboratory features...
  61. Shimizu D, Nomura K, Matsumoto Y, Nishida K, Taki T, Horiike S, et al. Small cell variant type of T-prolymphocytic leukemia with a four-year indolent course preceding acute exacerbation. Leuk Lymphoma. 2006;47:1170-2 pubmed
  62. Birhiray R, Shaw G, Guldan S, Rudolf D, Delmastro D, Santabarbara P, et al. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia. 2002;16:861-4 pubmed
    ..Here we report the outcome of two patients with CD4-positive T cell prolymphocytic leukemia treated with CAMPATH-1H...
  63. Vizcarra E, Martinez Climent J, Benet I, Marugan I, Terol M, Prosper F, et al. Identification of two subgroups of mantle cell leukemia with distinct clinical and biological features. Hematol J. 2001;2:234-41 pubmed
    ..However, the presence of certain features rarely observed in MCL, such as transformation to prolymphocytic leukemia (PLL) or indolent clinical course, suggests that MCLeu may represent a distinct disorder.
  64. de Lavallade H, Faucher C, Furst S, El Cheikh J, Vey N, Coso D, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplant. 2006;37:709-10 pubmed
  65. Espinet B, Sole F, Salido M, Lloveras E, Abella E, Besses C, et al. Application of cross-species color banding (RxFISH) in the study of T-prolymphocytic leukemia. Haematologica. 2000;85:607-12 pubmed
    ..The aim of the study was to test the RxFISH technique for better characterization of complex karyotypes in patients with T-prolymphocytic leukemia (T-PLL).
  66. Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O Brien S. Mature T-cell leukemias. Cancer. 2005;104:1808-18 pubmed
    ..Herein, we review the clinical and pathological features of mature T-cell leukemias...
  67. Tuset E, Matutes E, Brito Babapulle V, Morilla R, Catovsky D. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia. Leuk Lymphoma. 2001;42:1379-83 pubmed
    ..The reasons for the immunophenotypic changes are unknown but it is likely that loss of CD52 antigen expression contributed to the resistance to CAMPATH-1H in one of the patients when re-treated...
  68. Roberts J, Roberts G. B-Prolymphocytic leukemia: a case study. Clin Lab Sci. 2001;14:233-7 pubmed
    ..Immunophenotyping studies ultimately identified the nature of the disease as B-cell prolymphocytic leukemia with concomitant warm autoimmune hemolytic anemia...
  69. Valiev T, Vinogradova I, Chernova N, Mar in D, Volkova I, Petrova V, et al. [Remission in T-cell prolymphocytic leukemia during the FMC treatment course]. Ter Arkh. 2006;78:87-90 pubmed
  70. Nusz K, Pang N, Woog J. Periorbital edema as the initial presentation of T-cell prolymphocytic leukemia. Ophthalmic Plast Reconstr Surg. 2006;22:215-6 pubmed
    ..Laboratory tests revealed T-cell prolymphocytic leukemia. Despite systemic treatment, she died 2 weeks after presentation...
  71. Bacher U, Kern W, Schoch C, Hiddemann W, Haferlach T. Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH). Ann Hematol. 2004;83:349-55 pubmed
  72. Ogasawara T, Narita C, Kawauchi K. Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia. Leuk Res. 2007;31:403-6 pubmed
    We describe a 79-year-old man who had massive pleural effusion and a proliferation of prolymphocytic leukemia cells in the peripheral blood, bone marrow, and pleural effusion fluid...
  73. Fløisand Y, Brinch L, Gedde Dahl T, Tjønnfjord G. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab]. Tidsskr Nor Laegeforen. 2004;124:768-70 pubmed
    ..This may allow for further consolidating treatment with high-dose chemotherapy with autologous stem cell support or allogeneic stem cell transplantation...
  74. Kardum Skelin I, Planinc Peraica A, Ostojic Kolonic S, Radić Kristo D, Milas M, Vrhovac R, et al. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases]. Acta Med Croatica. 2008;62:351-64 pubmed
    ..The aim of the study was to identify the clinical and laboratory (hematologic, biochemical and morphological) prognostic parameters of chronic leukemic lymphoproliferative diseases (CLLPD)...
  75. Smith M, Singleton T, Balaraman S, Jaiyesimi I, O Malley B, Al Saadi A, et al. Case report: mantle cell lymphoma, prolymphocytoid variant, with leukostasis syndrome. Mod Pathol. 2004;17:879-83 pubmed
    ..While it is known that mantle cell lymphoma may have a leukemic phase, the degree of leukocytosis in this case exceeds that previously reported in the literature and resulted in a clinical syndrome of leukostasis...
  76. Panteli K, Bai M, Basioukas K, Vartholomatos G, Zioga K, Bourantas K. Skin and gingival lesions in a young woman with B-prolymphocytic leukemia (B-PLL). J Exp Clin Cancer Res. 2001;20:447-9 pubmed
    ..B-PLL has not been often associated with diffuse skin involvement or oral lesions. We present a 32 year-old woman in whom skin and gingival manifestations were the prominent clinical signs of disease relapse...
  77. Dunphy C, Perkins S. Mantle cell leukemia, prolymphocytoid type: a rarely described form. Leuk Lymphoma. 2001;41:683-7 pubmed
    ..A prolymphocytic leukemia with t(11;14)(q13;q32) has previously been reported; however, a complete flow cytometric immunophenotypic ..
  78. Stern M, Soulier J, Rosenzwajg M, Nakahara K, Canki Klain N, Aurias A, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene. 1993;8:2475-83 pubmed
    ..with a benign clonal proliferation in an ataxia telangiectasia patient and the second with a T cell prolymphocytic leukemia. Both translocations implicated the TCR alpha/delta locus and a common breakpoint region on chromosome ..
  79. Yuille M, Coignet L, Abraham S, Yaqub F, Luo L, Matutes E, et al. ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene. 1998;16:789-96 pubmed
    ..The mechanism of inactivation appeared to be unusual because multiple structural lesions on one allele were often observed...
  80. Valbuena J, Herling M, Admirand J, Padula A, Jones D, Medeiros L. T-cell prolymphocytic leukemia involving extramedullary sites. Am J Clin Pathol. 2005;123:456-64 pubmed
    T-cell prolymphocytic leukemia (T-PLL) can involve extramedullary sites, but the diagnosis is usually established by examination of blood and bone marrow...
  81. Moid F, Day E, Schneider M, Goldstein K, DePalma L. An indolent case of T-prolymphocytic leukemia with t(3;22)(q21;q11.2) and elevated serum beta2-microglobulin. Arch Pathol Lab Med. 2005;129:1164-7 pubmed
    We report a novel case of T-prolymphocytic leukemia, small cell variant, associated with complex cytogenetic findings including t(3;22)(q21;11.2) and elevated serum beta2-microglobulin...
  82. Grimwade D, Du M, Langabeer S, Rogers J, Solomon E. Screening for mutations of Bcl10 in leukaemia. Br J Haematol. 2000;109:611-5 pubmed
    ..Our results suggest that mutation of the Bcl10 gene as a mechanism of tumorigenesis is not associated with leukaemia...
  83. Del Giudice I, Davis Z, Matutes E, Osuji N, Parry Jones N, Morilla A, et al. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia. 2006;20:1231-7 pubmed
    B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis...
  84. Herling M, Teitell M, Shen R, Medeiros L, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 2003;101:5007-9 pubmed
    ..leukemias (1 of 14, 7%), or mature T-cell malignancies (1 of 112, < 1%), with the exception of T-prolymphocytic leukemia (T-PLL). All BT cases were also positive for the DC2-associated marker CD123...
  85. Nakazato T, Kizaki M. [Novel molecular therapy for acute promyelocytic leukemia (APL): application of the green tea component, catechin]. Rinsho Ketsueki. 2002;43:227-30 pubmed